Bayerische Motoren Werke ADR (BMWYY)

BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response (“DDR”) inhibitors, a category of drugs that work by blocking cancer cells’ capacity to fix their own damaged DNA, are growing well beyond the poly ADP ribose polymerase (“PARP”) inhibitor that first defined the category. DDR-inhibiting therapies generated an estimated $7 billion-plus in worldwide sales in 2025, and the wider oncology, diagnostics and precision medicine markets are expected to approach about $750 billion by 2030. A fresh wave of inhibitor classes is now taking shape as the next major opportunity. Standing at the leading edge of this shift is Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) ( Profile ), a Canadian clinical-stage oncology company developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme that participates in several distinct repair pathways. As the industry works toward the next generation of synthetic lethality assets, Onco-Innovations occupies a distinctive niche as it builds out its position within the biopharmaceutical and biotechnology space, alongside other established companies such as Merck & Co. Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), GSK plc (NYSE: GSK) and Gilead Sciences Inc. (NASDAQ: GILD), all of which are focused on…

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions of MS sufferers. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) ( Profile ) is determined working to change that outcome. The company is developing Lucid-MS, a patented, first-in-class drug candidate that approaches the disease from an entirely different angle by directly targeting the myelin sheath that MS destroys; the potential treatment is now preparing to move into phase 2 clinical trials. Quantum BioPharma stands among a group of companies pursuing therapies for neurological, autoimmune and immune-mediated conditions, a group that also includes Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX) and…

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

TULSA, OK - June 24, 2026 (NEWMEDIAWIRE) - Ladybug Resource Group, Inc. ("Ladybug" or the "Company") (OTC ID: LBRG) today announced the continued expansion of its strategic collaboration between its Jingdiao manufacturing division and Mino, a globally recognized provider of intelligent manufacturing and industrial automation solutions.

The search for new cancer therapies has traditionally focused on discovering entirely new drug candidates. While this approach has produced important breakthroughs, it is also expensive, time-consuming and carries a high risk of failure. Increasingly, researchers and biotechnology companies are exploring a complementary strategy: improving the way existing drugs are delivered to patients.

Researchers at Washington University (WashU) Medicine have conducted a small clinical trial testing a new vaccine against glioblastoma . The formulation was administered to nine patients who had undergone surgery and chemo-radiation therapy to remove their tumors. The results of this study show promise in extending tumor-free survival for a disease that is currently hard to treat.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced its inclusion in a BioMedWire editorial examining the growing market for DNA Damage Response inhibitor (“DDRi”) therapies and the next generation of cancer treatments targeting DNA repair pathways. The article highlights the company’s lead candidate, ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a key DNA repair enzyme involved in multiple repair mechanisms, positioning Onco-Innovations among emerging developers seeking to advance new synthetic lethality approaches in precision oncology.

Key Crafters Limited is addressing rising demand for mobile auto locksmith support as drivers seek faster help with lost keys, damaged fobs, and immobiliser programming across County Durham.

About 90% of men that undergo prostate cancer treatment, and almost 50% of men treated for different kinds of cancer suffer a degree of sexual dysfunction or erectile challenges. Most hardly ever open up about these issues and they suffer in silence. This needn’t be so, because there are many ways through which sexual challenges can be addressed for men with cancer.

BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion by 2030. New inhibitor classes are emerging as the next major wave. Sitting at the forefront of this shift is Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF), ( Profile ) a Canadian clinical-stage oncology company developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor that targets a DNA repair enzyme involved in multiple DNA repair pathways. As the field races to find the next generation of synthetic lethality assets, Onco-Innovations occupies a unique space as it strengthens its position in the biopharmaceutical and biotechnology sector, along with other leading companies, such as AstraZeneca plc (NYSE: AZN), Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD) and Foghorn Therapeutics Inc. (NASDAQ: FHTX), that are focused on developing therapies for serious…

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) ( Profile ) is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate that takes a fundamentally different approach by directly targeting the myelin sheath that MS destroys, and this new drug candidate is preparing to enter phase 2 clinical trials. Quantum BioPharma is one of several companies focused on the development and commercialization of therapies for neurological, autoimmune and immune-mediated diseases, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and…

The gift bow was still on the hood. For a lot of parents, that’s the dream ending. Years of school pickups, packed lunches, college planning and financial sacrifices finally lead to one unforgettable graduation

As demand for specialized automotive maintenance continues to grow, BMW repair Portland remains an important service category for drivers throughout the region. Local repair facilities such as Steve's Imports have seen continued interest from vehicle owners seeking experienced technicians capable of maintaining increasingly sophisticated European vehicles operating on Portland roads.

The property is located at 5483 Virginia Beach Boulevard in Virginia Beach, Virginia, along a high-traffic retail corridor near the intersection of Virginia Beach Boulevard and Newtown Road. Virginia Beach Boulevard carries approximately 37,000 vehicles per day. Newtown Road carries approximately 35,000 vehicles per day. The property benefits from immediate proximity to the Interstate 264 and Interstate 64 interchange, which generate approximately 212,000 and 179,000 vehicles per day, respectively. Surrounding national retailers include Topgolf, La-Z-Boy, BMW, Audi, Toyota, Honda, Subaru, Costco, Walmart, TJ Maxx, Burlington, CVS, AutoZone, Rooms To Go, Black Rifle Coffee Company, and Carvana. Sentara Leigh Hospital is located less than one mile from the property. Virginia Wesleyan University, with approximately 5,000 students, is situated nearby. Bayside High School, with approximately 2,000 students, is also located in close proximity. The JANAF Shopping Center, anchored by Walmart, BJ's Wholesale Club, and Goodwill, is adjacent to the corridor. More than 298,000 residents live within a five-mile radius of the property. The average household income within five miles exceeds $105,000. The population within three miles is approximately 110,440 residents. Virginia Beach is the most populous city in the Commonwealth of Virginia, with a population of approximately 455,000. The Virginia Beach MSA is ranked 37th in the United States by population size, with the broader Hampton Roads metropolitan area supporting a regional population exceeding 1.8 million. Norfolk International Airport is located within minutes of the property. Naval Air Station Oceana, a major military installation, is also situated within the city of Virginia Beach, Virginia.

Last year, Congress passed changes to Medicaid eligibility requirements and CMS was given a deadline to issue final rules on those work requirements. The federal agency has since published those final rules and enrollees on the Medicaid program need to acquaint themselves with these requirements to ensure they comply in order to retain their eligibility. We discuss some of those requirements.

OXNARD, CA - June 16, 2026 - PRESSADVANTAGE - Prestige Bodyworks, an Oxnard-based collision repair facility, is highlighting the critical importance of selecting certified repair shops as insurance companies report...

The FIFA World Cup started on June 11 and will end on July 19. 48 national teams are taking part, and this is an extra 16 teams when compared to the number of national teams that participated in the last edition that took place in Qatar in 2022. 100 matches are scheduled to be played across the U.S., Mexico and Canada.

June 16, 2026 -- A quirky design that redefined city driving and became a post-war cultural icon

A study conducted by a team at Mass General Brigham has found that people with a history of traumatic brain injury had a higher chance of dying as a result of brain cancer. The findings create an urgency to rethink how TBI cases are handled not just in the immediate aftermath but also over the long term.

LONDON - June 11, 2026 - On the outdoor parking bay outside HOUSE PARTY on Poland Street, a Unitree robot sat in the driver's seat of a BYD ATTO 2 DM-i, gripping the steering wheel as a THINKCAR diagnostic scanner ran a live vehicle scan beside it. A second robot stood outside the car, holding a diagnostic tablet toward the crowd as if demonstrating the reading.

CAR-T therapy has been transformational in treating many blood cancers, such as leukemia and lymphoma. However, this treatment approach hasn’t worked for solid tumors, and it also reaches a point and becomes ineffective in blood cancers. A new study just found a way to boost the lifespan and efficacy window of these important immune cells that help fight cancer.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

TULSA, OK - June 11, 2026 (NEWMEDIAWIRE) - Ladybug Resource Group, Inc. ("Ladybug" or the "Company") (OTC ID: LBRG) is pleased to announce a definitive milestone in its operational roadmap as its newly integrated manufacturing assets have successfully cleared the industry’s most rigorous 2026 environmental audits. This achievement is headlined by the rare and comprehensive Automated Painting and Surface Treatment Certification, a critical regulatory asset that secures the Company’s position as a mission-critical partner within the global Electric Vehicle (EV) ecosystem.

THE LUXURY RIDEJAIPUR'S MOST TRUSTED LUXURY CAR RENTAL+91 9462364444 · theluxuryride.in · Jaipur, Rajasthan 302020About The Luxury Ride — Jaipur's #1 Luxur

Hospitals have come under the spotlight as public concern about the health care cost crisis reaches unprecedented levels. The president of the American Hospital Association (AHA) wrote an article last week outlining how hospitals are taking steps to ensure that access and affordability issues are addressed so that Americans can continue to enjoy the high quality of care that they have come to expect from the health care system.